{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for azelaic root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Investigational
Source:
NCT00352131: Phase 1 Interventional Completed Non-colorectal Cancer
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
Biomed Pharmacother. Sep 2013;67(7):659-63.: Not Applicable Human clinical trial Completed Dry Eye Syndromes
Source URL:
Class:
PROTEIN
Eledoisin is an endecapeptide tachykinin receptor ligand. Originally it was isolated from salivary glands of Mediterranean octopod, Eledone moschata. Eledoisin is a powerful vasodilator and hypotensive agent in most animal species.
Status:
Designated
Source:
FDA ORPHAN DRUG:782420
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:810621
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:841321
Source URL:
Class:
PROTEIN
